OSTEONECROSIS MANDIBULAR POR BISFOSFONATO INTRAVENOSO

Resumen

Biphosphonates reduce the risk of skeletal events and are currently part of standards of therapy in myeloma and solid cancer. Recently, zoledronate and pamidronate have been linked to osteonecrosis of the jaw, specially after surgical dental procedures. We report a 72 year-old women with breast carcinoma who developed osteonecrosis of rigth jaw, after 24 months of therapy with pamidronate with a cumulative dose of 2160 mg. We discuss the pathogenic mechanisms, and review the recommendations on prevention and management of this new complication for neoplastic patients under prolonged therapy with biphosphonates.